Journal of Southern Medical University ›› 2006, Vol. 26 ›› Issue (02): 231-233.

Previous Articles     Next Articles

Expressions of Her-2, EGFR, PS-2 and ER in breast cancer and their clinical implications

XU Lei, BAI Zhong-hong, XU Ruan-cheng, YAN Hui, WANG Fang-ju, LUO Rong-cheng Department of Oncology, 91 Hospital of PLA, Jiaozuo 454003, China;Oncology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China   

  1. 解放军91医院肿瘤科; 南方医科大学南方医院肿瘤中心 河南焦作454003; 河南焦作454003; 广东广州510515;
  • Online:2006-02-20 Published:2006-02-20

Abstract: Objective To detect the expressions of human epidermal growth factor receptor 2 (Her-2), epidermal growth factor receptor (EGFR), presenilin 2 (PS-2) and estrogen receptor (ER) in breast cancer and discuss their clinical implications. Methods The expressions of Her-2, EGFR, PS-2 and ER were measured immunohistochemically in 108 patients with breast cancer. Results The positive expression rates of Her-2, EGFR, PS-2 and ER were 37.0%, 40.7%, 57.4% and 53.7% respectively in the breast cancer patients. The expression of Her-2 was not correlated with EGFR, but inversely correlated with PS-2 and ER. The expressions of Her-2 and EGFR, PS-2, ER were correlated with the histological grades (P<0.05), and Her-2, EGFR and ER expressions with lymph node metastasis (P<0.05). The expressions of Her-2, EGFR, PS-2 and ER did not correlate to the pathological types, patient’s age and tumor size (P>0.05). Conclusion Expressions of Her-2 and EGFR often suggests an unfavorable prognosis while expressions of PS-2 and ER suggest a more favorable one. Expressions of Her-2, EGFR, PS-2 and ER are useful prognostic factors in breast cancer patients.

CLC Number: